Medicenna's NEOCYT Melanoma Trial Data Presentation Looms at ASCO 2026

Event summary

  • Medicenna Therapeutics and Fondazione Melanoma Onlus will present a poster on the NEOCYT trial at the ASCO 2026 conference in Chicago, May 31st.
  • The NEOCYT trial is a Phase 1b study evaluating MDNA11, a Superkine IL-2 variant, in combination with nivolumab and potentially ipilimumab for high-risk melanoma patients.
  • The trial is investigator-initiated and sponsored by Fondazione Melanoma Onlus at the National Cancer Institute 'G. Pascale Foundation'.
  • MDNA11 is designed to preferentially activate cancer-killing immune cells while minimizing immunosuppressive effects.

The big picture

The NEOCYT trial represents a strategic pivot for Medicenna, focusing on a novel approach to IL-2 therapy designed to overcome the toxicity and limited efficacy of earlier iterations. The partnership with Fondazione Melanoma Onlus, a respected Italian melanoma research organization, lends credibility to the trial and expands Medicenna’s reach in the European oncology market. Success in this trial could significantly de-risk MDNA11 and accelerate its path to commercialization, but failure would likely necessitate a reassessment of the Superkine platform’s viability.

What we're watching

Clinical Efficacy
The ASCO presentation will be critical in assessing whether the combination of MDNA11 with existing therapies demonstrates meaningful clinical benefit in a high-risk melanoma population, particularly given the challenges in overcoming resistance to checkpoint inhibitors.
Regulatory Pathway
The trial's design and early data will influence the potential for accelerated regulatory approval pathways, especially given the unmet need for more effective melanoma treatments and the Fast Track/Orphan Drug designations for bizaxofusp.
Competitive Landscape
The NEOCYT trial’s results will be weighed against the performance of other novel IL-2 variants and combination immunotherapies in development, impacting Medicenna’s ability to secure partnerships and maintain a competitive edge.

Related topics

Pharmaceuticals Biotechnology